Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the Introduction of New Disease-Modifying Agents

被引：0
|
作者：
Pierluigi Russo
Alessandro Capone
Andrea Paolillo
Francesco Macchia
Federica Ranzato
Gianfranco Costantino
Luca Degli Esposti
Luciano Caprino
机构：
[1] University of Rome “La Sapienza”,Department of Human Physiology and Pharmacology
[2] Economics and Outcome Research,Clicon S.r.l., Health
[3] University of Rome “La Sapienza”,Department of Neurological Sciences
[4] University of Padua,Neurologic Clinic I
[5] Ospedale Civile di Foggia,undefined
来源：
Clinical Drug Investigation | 2004年 / 24卷
关键词：
Multiple Sclerosis; Glatiramer Acetate; Oxybutynin; Tolterodine; Progressive Multiple Sclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：409 / 420
页数：11
相关论文
共 50 条
  • [1] Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents
    Russo, P
    Capone, A
    Paolillo, A
    Macchia, F
    Ranzato, F
    Costantino, G
    Degli Esposti, L
    Caprino, L
    CLINICAL DRUG INVESTIGATION, 2004, 24 (07) : 409 - 420
  • [2] Disease-modifying therapies in relapsing-remitting multiple sclerosis
    Gonzalez-Andrade, Fabricio
    Luis Alcaraz-Alvarez, Jose
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 365 - 373
  • [3] Oral disease-modifying therapies for relapsing-remitting multiple sclerosis
    Thomas, Rachel Hutchins
    Wakefield, Richard A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (01) : 25 - 38
  • [4] Disease-modifying therapy in adult relapsing-remitting multiple sclerosis
    Rosenzweig, Tamara M.
    Hartman, Sarah
    MacKenzie, Elizabeth
    FORMULARY, 2010, 45 (08) : 252 - 262
  • [5] Established disease-modifying treatments in relapsing-remitting multiple sclerosis
    Oh, Jiwon
    O'Connor, Paul W.
    CURRENT OPINION IN NEUROLOGY, 2015, 28 (03) : 220 - 229
  • [6] Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
    Imani, Ali
    Golestani, Mina
    IRANIAN JOURNAL OF NEUROLOGY, 2012, 11 (03) : 87 - 90
  • [7] COST-UTILITY ANALYSIS OF DISEASE-MODIFYING DRUGS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN IRAN
    Imani, A.
    Golestani, M.
    Tabrizi, J. S.
    Janati, A.
    VALUE IN HEALTH, 2013, 16 (07) : A624 - A624
  • [8] Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis
    Roos, I.
    Malpas, C.
    Leray, E.
    Casey, R.
    Horakova, D.
    Havrdova, E. Kubala
    Debouverie, M.
    Patti, F.
    De Seze, J.
    Izquierdo, G.
    Eichau, S.
    Edan, G.
    Prat, A.
    Girard, M.
    Ozakbas, S.
    Grammond, P.
    Zephir, H.
    Ciron, J.
    Maillart, E.
    Moreau, T.
    Amato, M. P.
    Labauge, P.
    Alroughani, R.
    Buzzard, K.
    Skibina, O.
    Terzi, M.
    Laplaud, D.
    Berger, E.
    Grand'Maison, F.
    Lebrun-Frenay, C.
    Cartechini, E.
    Boz, C.
    Lechner-Scott, J.
    Clavelou, P.
    Stankoff, B.
    Prevost, J.
    Kappos, L.
    Pelletier, J.
    Shaygannejad, V.
    Yamout, B.
    Gerlach, O.
    Spitaleri, D.
    van Pesch, V.
    Gout, O.
    Turkoglu, R.
    Heinzlef, O.
    Thouvenot, E.
    Vukusic, S.
    Butzkueven, H.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 673 - 676
  • [9] Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis
    Roos, I.
    Malpas, C. B.
    Leray, E.
    Buzzard, K.
    Skibina, O.
    Lechner-Scott, J.
    McCombe, P.
    Slee, M.
    Butler, E.
    Macdonell, R.
    van der Walt, A.
    Hodgkinson, S.
    Barnett, M.
    Vucic, S.
    Vukusic, S.
    Butzkueven, H.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 : 6 - 7
  • [10] The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
    Bozkaya, Duygu
    Livingston, Terrie
    Migliaccio-Walle, Kristen
    Odom, Tanner
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 297 - 302
12345